暫無數據
代碼股票名稱
最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
美股期權個股詳情
MDRX240621P10000
- 1.90
- -1.80-48.65%
延時15分鐘行情收盤價 05/28 14:31 (美東)
1.90最高價1.90最低價
1.90今開3.70昨收4張成交量568張未平倉合約數10.00行權價760.00成交額124.35%引伸波幅-7.43%溢價2024/06/21到期日1.25内在价值100合約乘數24天距到期日0.65時間價值100合約規模美式期權類型-0.5975Delta0.1383Gamma4.61槓桿倍數-0.0216Theta-0.0041Rho-2.75有效槓桿0.0087Vega
分時
- 5日
- 日K
新聞
TD Cowen 將 Veradigm 維持在買入水平
TD Cowen 將 Veradigm 維持在買入水平
快訊 | 道明考恩維持對Veradigm的買入，將目標股價下調至15美元
Veradigm 分析師評級
日期上行/下行分析師公司目標股價變動評級變動之前/當前評級 2024 年 5 月 28 日 81.25% TD Cowen 26 美元 → 15 美元維持在 2024 年 3 月 19 日買入 20.84% 德意志銀行 15 美元 → 10 美元下調評級 Bu
快訊 | Veradigm——不打算任命任何長期高管，同時另行宣佈正在探索戰略替代方案
快訊 | 湯姆·蘭根被任命爲Veradigm的臨時首席執行官
快訊 | Veradigm Inc：將探索潛在的戰略替代方案，其中可能包括出售、合併、戰略業務合併或其他交易
評論
Veradigm's promising ROCE trend and its capacity to yield higher returns on less capital is noteworthy. Despite the stock's five-year decline, these trends may warrant further investigation.
Returns At Veradigm (NASDAQ:MDRX) Are On The Way UpThe acquisition is a major chance for Veradigm to broaden its revenue services and utilize more capabilities, says Brian Hall, CEO of Koha Health, seeing it as an opportunity to gain more resources for their client's financial triumph and upgraded patient experience.
Though Veradigm seems undervalued, the pessimistic forecast implies notable risk, raising doubts about intensifying MDRX portfolio exposure. Despite present undervaluation, potential investors considering an entry now must assess negative future growth predictions.
$Veradigm(MDRX.US$2022年業績至今未出，5年來營收除2020年下滑8%以外增長了4年，平均增速僅有1.6%，營業利潤從2018到2020年均虧損，2021年靠大幅削減費用扭虧達到0.89億，淨利潤靠非經營收入達到1.3億。
2022前3季度營收增長6.2%，營業利潤萎縮40%，淨利潤受停止經營利潤影響重新進入虧損區間。
業績延誤通常不是好現象，加上近期財務數據的大起大落，暫時缺乏投資價值。
2022前3季度營收增長6.2%，營業利潤萎縮40%，淨利潤受停止經營利潤影響重新進入虧損區間。
業績延誤通常不是好現象，加上近期財務數據的大起大落，暫時缺乏投資價值。
已翻譯
$Veradigm(MDRX.US$ reports earnings for the last 3 months and a full year on February 25th. after recently pulling back I feel like this talk is at a good price point to make an entry and also try to front run the earnings call strategy groups who usually only seem to look a week ahead. this was a position I wanted to enter before I noticed this scenario so it works out well. having any kind of telemedicine in your portfolio right now is a good thing I think...
1
閱讀更多